Regulatory Replimune rebounds to win FDA approval of melanoma drug BioPharma DiveThe accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.OncologyRead full story pharminent August 6, 2026 (Last updated: August 8, 2026) BioPharma Dive The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists. Oncology Read full story Post navigation Previous: FDA Approves Moderna’s mFlusiva, the First mRNA-Based Seasonal Flu VaccineNext: Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments Related Stories Regulatory Jazz secures FDA approval for Ziihera in advanced HER2+ GEA pharminent August 26, 2026 Regulatory Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test pharminent August 25, 2026 Regulatory Expanded US Imaavy approval first ever for wAIHA pharminent August 25, 2026
